Q32 Bio (QTTB) Change in Account Payables (2017 - 2026)
Q32 Bio's (QTTB) quarterly Change in Account Payables came in at -$226000.0 in Q1 2026, up 18.41% year-on-year from -$190859.8 in Q1 2025, and down 140.43% quarter-over-quarter from -$94000.0 in Q4 2025.
Q32 Bio (QTTB) Change in Account Payables (2017 - 2026) Analysis & Trends
Q32 Bio's Change in Account Payables history runs 10 years deep, the most recent figure standing at -$226000.0 for Q1 2026.
- On a quarterly basis, Change in Account Payables rose 18.41% year-over-year to -$226000.0 in Q1 2026; TTM through Mar 2026 was -$2.1 million, a 8.41% increase from a year earlier, with the FY2025 full-year figure at -$2.1 million, down 102.3% from the prior year.
- Change in Account Payables retreated to -$226000.0 in Q1 2026 per QTTB's latest filing, from -$94000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $7.7 million in Q1 2022 and bottomed at -$6.1 million in Q2 2022.
- The 5-year median for Change in Account Payables is -$94000.0 (2025), against an average of -$136882.4.
- Across the five-year window, Change in Account Payables jumped 7801.0% in 2022 and sank 2850.0% in 2024, its largest moves.
- Year by year, Change in Account Payables stood at -$3.7 million in 2022, then surged by 144.39% to $1.6 million in 2023, then climbed by 5.61% to $1.7 million in 2024, then sank by 105.43% to -$94000.0 in 2025, then slumped by 140.43% to -$226000.0 in 2026.
- Per Business Quant, the three latest QTTB Change in Account Payables figures stand at -$226000.0 (Q1 2026), -$94000.0 (Q4 2025), and $63000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | - |
| 2 | Nanobiotix | 1,911.11 Bn | 1,911.05 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.81 Bn | 463.02 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 122.92 Bn | 115.68 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | - |
| 10 | Q32 Bio | 217.35 Mn | 166.60 Mn | - | -226,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -226,000.00 |
| Mar 31, 2026 | -226,000.00 |
| Dec 31, 2025 | -94,000.00 |
| Dec 31, 2025 | -94,000.00 |
| Sep 30, 2025 | 63,000.00 |
| Sep 30, 2025 | 63,000.00 |
| Jun 30, 2025 | -1.80 Mn |
| Jun 30, 2025 | -1.80 Mn |
| Mar 31, 2025 | -277,000.00 |
| Mar 31, 2025 | -277,000.00 |
| Dec 31, 2024 | 1.73 Mn |
| Dec 31, 2024 | 1.73 Mn |
| Sep 30, 2024 | -1.23 Mn |
| Sep 30, 2024 | -1.23 Mn |
| Jun 30, 2024 | -2.48 Mn |
| Jun 30, 2024 | -2.48 Mn |
| Mar 31, 2024 | 928,000.00 |
| Mar 31, 2024 | 928,000.00 |
| Dec 31, 2023 | 1.64 Mn |
| Dec 31, 2023 | 1.64 Mn |